Chronic Refractory Cough

Chronic refractory cough is a persistent cough that continues despite appropriate assessment and treatment of identifiable causes. It is associated with substantial effects on sleep, work, social participation, physical comfort, and psychological well-being. Clinical management is complicated by overlapping respiratory, gastrointestinal, allergic, neurological, and medication-related contributors, while some patients exhibit cough hypersensitivity in the absence of an adequately treatable underlying condition.

The care landscape is moving from repeated empirical treatment toward structured evaluation of common causes, medication exposure, airway disease, reflux-related symptoms, upper-airway conditions, and cough hypersensitivity. Increasing attention to validated symptom assessment, specialist referral, speech-language therapy, behavioral approaches, and appropriately selected pharmacological interventions is encouraging more individualized care. Persistent gaps remain in timely referral, diagnostic consistency, access to specialists, and recognition of patients whose cough has multiple contributing mechanisms.

Artificial intelligence may support chronic cough care by analyzing cough sounds, electronic health records, symptom patterns, imaging, and treatment responses. Potential applications include identifying patients who warrant specialist assessment, distinguishing clinically relevant cough phenotypes, monitoring response outside the clinic, and reducing documentation burden. Reliable deployment requires representative datasets, clinically validated performance, privacy safeguards, explainability, and human oversight; algorithmic tools should complement rather than replace clinical evaluation.

North America generally benefits from established specialist pathways and broader access to advanced diagnostics, although care can remain fragmented. Europe combines guideline-oriented practice with variation in referral processes and reimbursement across countries. Asia-Pacific includes highly developed specialist systems alongside areas where diagnostic access and awareness are more limited. Latin America faces uneven availability of respiratory and specialty services, while the Middle East shows substantial variation between well-resourced urban centers and underserved populations. Africa continues to encounter constraints involving specialist workforce capacity, diagnostic infrastructure, medication access, and competing respiratory-health priorities.

ASEAN members differ considerably in specialist availability, diagnostic infrastructure, and access to newer therapies, making regional education and referral coordination important. BRICS economies have large patient populations but heterogeneous coverage, urban–rural access, and research capacity. The European Union benefits from shared clinical collaboration but retains national differences in reimbursement and service organization. G7 countries typically have stronger research and specialist networks, while NATO members span markedly different health-system capabilities. GCC states often have well-resourced urban services, alongside continuing needs in workforce development, standardized pathways, and equitable access for mobile and underserved populations.

Australia and Canada have strong clinical and research capabilities but must address geographic access. Brazil, Mexico, India, and South Africa face pronounced regional and urban–rural differences in specialist care. China is expanding advanced healthcare capacity while managing wide variation between major cities and less-served areas. Japan and South Korea have sophisticated medical systems with opportunities to improve recognition and longitudinal symptom monitoring. France, Germany, Italy, Spain, and the United Kingdom have established respiratory services, but referral thresholds, reimbursement arrangements, and access to specialist interventions differ. Russia’s care environment reflects substantial geographic variation and resource constraints. In the United States, specialist expertise and diagnostic options are extensive, while affordability, insurance coverage, and fragmented care can influence patient journeys.

Industry leaders should support evidence-based diagnostic pathways that separate treatable causes from refractory disease and define clear referral criteria. Development programs should use clinically meaningful endpoints, validated patient-reported outcomes, objective cough monitoring where appropriate, and subgroup analyses that reflect real-world diversity. Partnerships with clinicians, patients, speech-language professionals, payers, and health systems can improve implementation. Digital and artificial-intelligence tools should be introduced through prospective validation, transparent governance, cybersecurity controls, and monitoring for performance differences across populations. Education initiatives should emphasize early recognition, medication review, avoidance of unnecessary repeated treatment, and continuity of follow-up.

This executive summary uses a structured qualitative synthesis of established clinical concepts relevant to chronic refractory cough, including definitions, diagnostic challenges, treatment pathways, patient burden, digital-health opportunities, and health-system variation. Regional, group, and country observations are framed as comparative context rather than quantitative estimates. Interpretation should be updated as clinical guidelines, regulatory positions, diagnostic technologies, and evidence for pharmacological, behavioral, and artificial-intelligence interventions evolve.

Chronic refractory cough remains a complex condition requiring accurate exclusion of treatable causes, recognition of cough hypersensitivity, and sustained attention to patient-reported burden. Progress will depend on coordinated multidisciplinary services, stronger diagnostic consistency, appropriately evaluated therapies, and responsible use of digital tools. Leaders who connect clinical evidence with equitable access, transparent validation, and long-term follow-up can help reduce unnecessary treatment cycles and improve the experience of patients living with persistent cough.